Sun Q, Liu R, Zhang H, Zong L, Jing X, Ma L
PeerJ. 2023; 11:e16526.
PMID: 38077434
PMC: 10704988.
DOI: 10.7717/peerj.16526.
Englisch C, Moik F, Thaler J, Koder S, Mackman N, Preusser M
Haematologica. 2023; 109(4):1128-1136.
PMID: 37822244
PMC: 10985431.
DOI: 10.3324/haematol.2023.283581.
Hassan N, Efing J, Kiesel L, Bendas G, Gotte M
Cancers (Basel). 2023; 15(5).
PMID: 36900315
PMC: 10001432.
DOI: 10.3390/cancers15051524.
Khazdair M, Boskabady M
Front Med (Lausanne). 2022; 9:791914.
PMID: 35572987
PMC: 9106304.
DOI: 10.3389/fmed.2022.791914.
Xing M, Yang Y, Huang J, Fang Y, Jin Y, Li L
Genes Genomics. 2022; 44(7):801-812.
PMID: 35567715
DOI: 10.1007/s13258-022-01258-5.
Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.
Wojtukiewicz M, Mysliwiec M, Matuszewska E, Sulkowski S, Zimnoch L, Politynska B
Biomolecules. 2021; 11(5).
PMID: 33947134
PMC: 8146081.
DOI: 10.3390/biom11050663.
Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds.
Menyailo M, Tretyakova M, Denisov E
Int J Mol Sci. 2020; 21(5).
PMID: 32121639
PMC: 7084665.
DOI: 10.3390/ijms21051696.
Tissue factor expression predicts outcome in children with neuroblastoma: A retrospective study.
Sherief L, Hassan T, Zakaria M, Fathy M, Eshak E, Bebars M
Oncol Lett. 2019; 18(6):6347-6354.
PMID: 31807159
PMC: 6876335.
DOI: 10.3892/ol.2019.11021.
Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis.
Hisada Y, Mackman N
Semin Thromb Hemost. 2019; 45(4):385-395.
PMID: 31096306
PMC: 6546519.
DOI: 10.1055/s-0039-1687894.
Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2.
Lucotti S, Cerutti C, Soyer M, Gil-Bernabe A, Gomes A, Allen P
J Clin Invest. 2019; 129(5):1845-1862.
PMID: 30907747
PMC: 6486338.
DOI: 10.1172/JCI121985.
Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1.
Arnason T, Harkness T
Cancers (Basel). 2015; 7(4):2063-82.
PMID: 26501324
PMC: 4695877.
DOI: 10.3390/cancers7040877.
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M, Vollan H, Sahlberg K, Jernstrom S, Kaveh F, Lingjaerde O
Breast Cancer Res. 2015; 17:44.
PMID: 25882602
PMC: 4423106.
DOI: 10.1186/s13058-015-0548-5.
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood.
Li J, Sharkey C, Huang D, King M
Cell Mol Bioeng. 2015; 8(1):137-150.
PMID: 25798204
PMC: 4361771.
DOI: 10.1007/s12195-015-0381-z.
Tissue factor in tumor microenvironment: a systematic review.
Han X, Guo B, Li Y, Zhu B
J Hematol Oncol. 2014; 7:54.
PMID: 25084809
PMC: 4237870.
DOI: 10.1186/s13045-014-0054-8.
Microenvironmental regulation of tumor progression and metastasis.
Quail D, Joyce J
Nat Med. 2013; 19(11):1423-37.
PMID: 24202395
PMC: 3954707.
DOI: 10.1038/nm.3394.
TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells.
Stavik B, Skretting G, Olstad O, Sletten M, Vigeland M, Sandset P
PLoS One. 2012; 7(10):e47184.
PMID: 23071754
PMC: 3465304.
DOI: 10.1371/journal.pone.0047184.
Modeling and simulation of procoagulant circulating tumor cells in flow.
Lee A, Tormoen G, Kanso E, McCarty O, Newton P
Front Oncol. 2012; 2:108.
PMID: 23050240
PMC: 3442195.
DOI: 10.3389/fonc.2012.00108.
Adhesion receptors as therapeutic targets for circulating tumor cells.
Li J, King M
Front Oncol. 2012; 2:79.
PMID: 22837985
PMC: 3402858.
DOI: 10.3389/fonc.2012.00079.
Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice.
Williams L, Tucker T, Koenig K, Allen T, Rao L, Pendurthi U
Am J Respir Cell Mol Biol. 2011; 46(2):173-9.
PMID: 21852688
PMC: 3297168.
DOI: 10.1165/rcmb.2011-0276OC.
Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility.
Stavik B, Skretting G, Aasheim H, Tinholt M, Zernichow L, Sletten M
BMC Cancer. 2011; 11:357.
PMID: 21849050
PMC: 3175223.
DOI: 10.1186/1471-2407-11-357.